News
-
-
-
PRESS RELEASE
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Bausch Health Companies Inc. and Salix Pharmaceuticals win U.S. Court of Appeals case over XIFAXAN, affirming FDA approval delay until Oct. 2029. Statements from CEOs included -
-
PRESS RELEASE
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Bausch Health, Canada Inc. announces availability of ARAZLO lotion for acne treatment through BC PharmaCare. ARAZLO offers unique formulation technology to enhance patient tolerability -
-
-
-
PRESS RELEASE
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
Bausch Health's UCERIS listed on public drug plans in 5 Canadian provinces. The rectal foam treats mild to moderate ulcerative colitis. Patients gaining insured access to effective treatment -
